New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer

Document Type : Research Articles

Authors

1 Institude of Biology, School of Pharmaceutical and Biological Science, University of south China

2 Reproductive Health Hospital of Nanhua-Xinghui in Hengyang City, Heng Yang 421001, Hunan Province, China.

3 Institute of Biological Science, The Key Laboratory of Biological Toxicology and Ecological Restoration of Hengyang City, School of Pharmaceutical and Biological Science, China.

4 Institute of Biological Science, The Key Laboratory of Biological Toxicology and Ecological Restoration of Hengyang City, School of Pharmaceutical and Biological Science,China

5 Department of Anatomy, University of South China, Heng Yang 421001, Hunan Province, China

6 Institute of Pharmacy and Pharmacology, University of South China, China

7 Institute of Biological Science, The Key Laboratory of Biological Toxicology and Ecological Restoration of Hengyang City, School of Pharmaceutical and Biological Science, China

8 Institute of Biology, School of Pharmaceutical and Biological Science, University of South China

Abstract

 
mTOR, the mammalian target of rapamycin, is a conserved serine/threonine kinase which belongs to the phosphatidyl-linositol kinase-related kinase (PIKK) family. It has two complexes called mTORC1 and mTORC2. It is well established that mTOR plays important roles in cell growth, proliferation and differentiation. Over-activation of the mTOR pathway is considered to have a relationship with the development of many types of diseases, including polycystic ovary syndrome (PCOS) and ovarian cancer (OC). mTOR pathway inhibitors, such as rapamycin and its derivatives, can directly or indirectly treat or relieve the symptoms of patients suffering from PCOS or OC. Moreover, mTOR inhibitors in combination with other chemical-molecular agents may have extraordinary efficacy. This paper will discuss links between mTOR signaling and PCOS and OC, and explore the mechanisms of mTOR inhibitors in treating these two diseases, with conclusions regarding the most effective therapeutic approaches.

Keywords

Asian Pacific Journal of Cancer Prevention
Volume 17, Issue 12
December 2016
Pages 5087-5094

Files

History

  • Receive Date: 09 October 2016
  • Revise Date: 14 December 2016
  • Accept Date: 16 January 2017

Share

How to cite

Statistics